Ayano Nakazawa

  • Citations Per Year
Learn More
A standard therapeutic regimen of a 5-HT₃ receptor antagonist antiemetic agent+dexamethasone was administered as antiemetic therapy for 29 patients who received chemotherapy for colorectal cancer in(More)
  • 1